Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental condition that causes hyperactivity and impulsivity in children and adults. If left untreated ...
Study Finds on MSN
FDA-cleared brain stimulation device for ADHD works no better than placebo in major trial
In A Nutshell • A brain stimulation device cleared by the FDA in 2019 failed to beat placebo in a rigorous 150-participant ...
Launches of Tuzulby® methylphenidate prolonged-release chewable tablets and Paxneury® guanfacine prolonged-release tablets, also in 5mg, 6mg, and 7mg strengthsTwo differentiated treatments exemplify ...
Stimulant drugs and another medication – atomoxetine – appear to be the best treatment for managing symptoms of ADHD, a study suggests. Monique Wüstenhagen/dpa Talking therapy and brain stimulation ...
It has long been assumed that psychostimulants help those with ADHD by acting on the brain’s attention circuitry. However, ...
SHANGHAI, Jan. 8, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that China's National Medical Products Administration (NMPA) has approved the New Drug ...
German CNS-focused specialist Neuraxpharm Group announced the launches in Europe of Tuzulby (methylphenidate hydrochloride) prolonged-release chewable tablets and Paxneury (guanfacine) ...
This article was reviewed by Lynn Marie Morski, MD, JD. Key Takeaways: ADHD and menopause symptoms can overlap, and one ...
For years, people thought that attention deficit hyperactivity disorder (ADHD) was a problem that only kids had. It was ...
Ark Biopharmaceutical Receives China Marketing Authorization for Azstarys® for the Treatment of ADHD
Shanghai Ark Biopharmaceutical Co., Ltd. ('ArkBio') today announced that China's National Medical Products Administration (NMPA) has approved the New Drug Application for Serdexmethylphenidate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results